Immunitybio vs Regenxbio
Regenxbio is the larger business, with $170m of revenue in fiscal 2025 against $113m for Immunitybio (1.5 times as much). Immunitybio grew faster (668.3% against 104.5%). Regenxbio kept more of each dollar of sales as profit: a net margin of -113.8% against -310.2%.
| Latest fiscal year | ImmunitybioIBRX, 2025 | RegenxbioRGNX, 2025 |
|---|---|---|
| Revenue | $113m | $170m |
| Revenue growth | 668.3% | 104.5% |
| Net income | −$351m | −$194m |
| Operating margin | -226.0% | -94.6% |
| Net margin | -310.2% | -113.8% |
| Return on equity | — | -107.0% |
| Free cash flow | −$309m | −$126m |
| Cash | $88.3m | $34.5m |
| Total debt | $326m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 691 | 371 |
| Market value | $8.69bn | $408m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 19 (Weak) |
| Insider trades, 12 months | 0 buys, 16 sales | 2 buys, 5 sales |